Cargando…

High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms

Tumor heterogeneity is a key reason for therapeutic failure and tumor recurrence in glioblastoma (GBM). Our chimeric antigen receptor (CAR) T cell (2173 CAR T cells) clinical trial (NCT02209376) against epidermal growth factor receptor (EGFR) variant III (EGFRvIII) demonstrated successful traffickin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thokala, Radhika, Binder, Zev A., Yin, Yibo, Zhang, Logan, Zhang, Jiasi Vicky, Zhang, Daniel Y., Milone, Michael C., Ming, Guo-li, Song, Hongjun, O’Rourke, Donald M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461175/ https://www.ncbi.nlm.nih.gov/pubmed/34568006 http://dx.doi.org/10.3389/fonc.2021.664236

Ejemplares similares

Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas
por: Yin, Yibo, et al.
Publicado: (2018)

Production of scFv-Conjugated Affinity Silk Powder by Transgenic Silkworm Technology
por: Sato, Mitsuru, et al.
Publicado: (2012)

Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
por: Zhang, Chengcheng, et al.
Publicado: (2023)

Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
por: Kang, Chung Hyo, et al.
Publicado: (2020)

scFv Antibody: Principles and Clinical Application
por: Ahmad, Zuhaida Asra, et al.
Publicado: (2012)

Screening of a ScFv Antibody With High Affinity for Application in Human IFN-γ Immunoassay
por: Yang, Hang, et al.
Publicado: (2018)

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
por: Song, Edward Z., et al.
Publicado: (2022)

Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein
por: Pavoni, Emiliano, et al.
Publicado: (2006)

Development and validation of scFv-conjugated affinity silk protein for specific detection of carcinoembryonic antigen
por: Sato, Mitsuru, et al.
Publicado: (2017)

Nonspecificity in a nonimmune human scFv repertoire
por: Kelly, Ryan L., et al.
Publicado: (2017)

“Stapling” scFv for multispecific biotherapeutics of superior properties
por: Boucher, Lauren E., et al.
Publicado: (2023)

Empowering scFv with effector cell functions for improved anticancer therapeutics
por: Zhang, Hongtao
Publicado: (2013)

Isolation and characterization of human anti-CD20 single-chain variable fragment (scFv) from a Naive human scFv library
por: Shams, Nasir, et al.
Publicado: (2022)

Toward Low-Cost Affinity Reagents: Lyophilized Yeast-scFv Probes Specific for Pathogen Antigens
por: Gray, Sean A., et al.
Publicado: (2012)

Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells
por: Hutt, Meike, et al.
Publicado: (2018)

High scFv-receptor affinity does not enhance the antitumor activity of HER2 retargeted measles virus
por: Suksanpaisan, Lukkana, et al.
Publicado: (2014)

Clonal array profiling of scFv-displaying phages for high-throughput discovery of affinity-matured antibody mutants
por: Kiguchi, Yuki, et al.
Publicado: (2020)

The effects of N-terminal insertion into VSV-G of an scFv peptide
por: Dreja, Hanna, et al.
Publicado: (2006)

Integrating scFv into xMAP Assays for the Detection of Marine Toxins
por: Shriver-Lake, Lisa C., et al.
Publicado: (2016)

The Four-State Equilibrium Unfolding of a scFv Antibody Fragment
por: Pedroso, Idolka, et al.
Publicado: (2002)

Humanization and directed evolution of the selenium-containing scFv phage abzyme
por: Xu, Yan, et al.
Publicado: (2018)

Engineered Human Monoclonal scFv to Receptor Binding Domain of Ebolavirus
por: Densumite, Jaslan, et al.
Publicado: (2021)

Generation and evaluation of IgY-scFv based mimetics against canine parvovirus
por: Ge, Shikun, et al.
Publicado: (2021)

Antigen specificity and tumour targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivatives.
por: Jackson, H., et al.
Publicado: (1998)

Production of scFv-conjugated affinity silk film and its application to a novel enzyme-linked immunosorbent assay
por: Sato, Mitsuru, et al.
Publicado: (2014)

High-Throughput Generation of Bipod (Fab × scFv) Bispecific Antibodies Exploits Differential Chain Expression and Affinity Capture
por: Nesspor, Thomas C., et al.
Publicado: (2020)

Isolation and identification of an scFv antibody against nucleocapsid protein of SARS-CoV
por: Zhao, Aizhi, et al.
Publicado: (2007)

Preparation and Directed Evolution of Anti-Ciprofloxacin ScFv for Immunoassay in Animal-Derived Food
por: Wang, Fangyu, et al.
Publicado: (2021)

Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors
por: Yang, Fan, et al.
Publicado: (2023)

Production and characterisation of a recombinant scFv reactive with human gastrointestinal carcinomas
por: Kim, D-J, et al.
Publicado: (2002)

Generation and Characterization of an scFv Directed against Site II of Rabies Glycoprotein
por: Aavula, Shukra M., et al.
Publicado: (2011)

Early Detection of NSCLC with scFv Selected against IgM Autoantibody
por: Pedchenko, Tetyana, et al.
Publicado: (2013)

Development and identification of fully human scFv-Fcs against Staphylococcus aureus
por: Nian, Siji, et al.
Publicado: (2016)

Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E
por: Miethe, Sebastian, et al.
Publicado: (2015)

Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes
por: Alric, Christophe, et al.
Publicado: (2018)

Generation of a Fully Human scFv that binds Tumor-Specific Glycoforms
por: Lu, Zhongpeng, et al.
Publicado: (2019)

Characterization and analysis of scFv-IgG bispecific antibody size variants
por: Cao, Mingyan, et al.
Publicado: (2018)

Development and in vitro characterization of a humanized scFv against fungal infections
por: Di Mambro, Tomas, et al.
Publicado: (2022)

Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv
por: Ping, Yu, et al.
Publicado: (2020)

Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies
por: Bhatta, Pallavi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7plrmh9iseo28og4v9f21g3tsa